Chapman, SR, Aladul, M and Fitzpatrick, R (2017) Patient's Understanding and Attititudes Towards Infliximab and Etanercept Biosimilars. BioDrugs. pp. 1-8. ISSN 1172-7039

[thumbnail of Patients' Understanding and Attitudes Towards Infliximab ans Etanercept Biosimilars; Result of a UK Web based survey.docx] Text
Patients' Understanding and Attitudes Towards Infliximab ans Etanercept Biosimilars; Result of a UK Web based survey.docx - Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (60kB)


Infliximab and etanercept biosimilars present significant potential cost savings to the NHS. Patients need to be involved in the decision to use these medicines but there is a limited published literature on their knowledge and attitudes about these biosimilars.

To investigate ankylosing spondylitis and rheumatoid arthritis patients’ knowledge and attitudes towards infliximab and etanercept biosimilars in UK.

A self-administered, web-survey conducted among the members of the National Rheumatoid Arthritis Society and the National Ankylosing Spondylitis Society in the UK between 2 March 2017 and 2 June 2017.

A total of 182 patients participated in this survey. The majority of participants (73%) were on etanercept. 66%-80% of patients on originator biologic and biosimilars respectively understood what biosimilars were. Patients who were currently on biosimilars had greater confidence in their effectiveness and the doctor’s decision to initiate than those who were originally on originator biologics that doctors proposed to switch to biosimilars. The majority (82%) of participants on biosimilars thought that biosimilars help saving money for the NHS, while just over half (54%) of participants on the originator biologics thought the cost of treatment should not be considered when prescribing biosimilars.

Survey participants had a good knowledge and understanding of biosimilars. Participants on biosimilars were confident and positive about biosimilars’ safety, efficacy and switching, whereas participants on the originator biologics were more reluctant to switch to biosimilars. Those patients who expressed concerns felt that more clinical trials on switching biosimilars, better communication and reassurance by healthcare professional teams and further involvement in decision-making would increase their acceptance of biosimilars.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Springer at - please refer to any applicable terms of use of the publisher.
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy
Depositing User: Symplectic
Date Deposited: 03 Aug 2017 12:56
Last Modified: 03 Sep 2018 08:42

Actions (login required)

View Item
View Item